|
US20070054355A1
(en)
|
2003-03-05 |
2007-03-08 |
Yuval Reiss |
Cbl-b polypeptides, complexes and related methods
|
|
WO2007072225A2
(en)
|
2005-12-01 |
2007-06-28 |
Medical Prognosis Institute |
Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
|
|
WO2008033403A2
(en)
|
2006-09-13 |
2008-03-20 |
The Trustees Of Columbia University In The City Of New York |
Agents and methods to elicit anti-tumor immune response
|
|
AT506041A1
(de)
|
2007-12-10 |
2009-05-15 |
Univ Innsbruck |
Verfahren zur erhöhung der immunreaktivität
|
|
PL2242749T3
(pl)
|
2008-02-05 |
2013-09-30 |
Hoffmann La Roche |
Nowe pirydynony i pirydazynony
|
|
EP2440204B1
(en)
|
2009-06-12 |
2013-12-18 |
Bristol-Myers Squibb Company |
Nicotinamide compounds useful as kinase modulators
|
|
EP2566869B1
(en)
|
2010-05-07 |
2016-03-02 |
Gilead Connecticut, Inc. |
Pyridone and aza-pyridone compounds and methods of use
|
|
AR082590A1
(es)
|
2010-08-12 |
2012-12-19 |
Hoffmann La Roche |
Inhibidores de la tirosina-quinasa de bruton
|
|
EP2471548A1
(de)
|
2010-12-28 |
2012-07-04 |
Apeiron Biologics AG |
siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
|
|
UA111756C2
(uk)
|
2011-11-03 |
2016-06-10 |
Ф. Хоффманн-Ля Рош Аг |
Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
|
|
MX2014005282A
(es)
|
2011-11-03 |
2014-05-30 |
Hoffmann La Roche |
Compuestos de 8-fluoroftalazin-1 (2h) -ona.
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
WO2014040965A1
(en)
|
2012-09-13 |
2014-03-20 |
F. Hoffmann-La Roche Ag |
Inhibitors of bruton's tyrosine kinase
|
|
US10308707B2
(en)
|
2013-12-02 |
2019-06-04 |
Aaron Diamond Aids Research Center |
Bispecific HIV-1-neutralizing antibodies
|
|
US9382246B2
(en)
|
2013-12-05 |
2016-07-05 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
MX2017015574A
(es)
|
2015-06-02 |
2018-08-09 |
Pharmacyclics Llc |
Inhibidores de tirosina quinasa de bruton.
|
|
AU2016297362B2
(en)
|
2015-07-17 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
Oxadiazole derivatives useful as HDAC inhibitors
|
|
HUE066460T2
(hu)
|
2016-10-26 |
2024-08-28 |
Iovance Biotherapeutics Inc |
A kriokonzervált tumor infiltráló limfociták restimulációja
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
CA3042297A1
(en)
|
2016-11-22 |
2018-05-31 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
WO2018106870A1
(en)
|
2016-12-08 |
2018-06-14 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating cdk4/6-mediated cancer
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
EP3743063A4
(en)
|
2018-01-26 |
2021-10-20 |
Nurix Therapeutics, Inc. |
CBL-B INHIBITORS AND THEIR METHODS OF USE
|
|
EP3746426A4
(en)
|
2018-01-29 |
2021-12-29 |
Dana Farber Cancer Institute, Inc. |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
CN112584852A
(zh)
*
|
2018-06-19 |
2021-03-30 |
百欧恩泰美国公司 |
新抗原及其用途
|
|
MX2021004191A
(es)
|
2018-10-15 |
2021-05-27 |
Nurix Therapeutics Inc |
Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
|
|
US12582722B2
(en)
|
2019-02-13 |
2026-03-24 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
|
|
CA3136348A1
(en)
|
2019-04-09 |
2020-10-15 |
Nurix Therapeutics, Inc. |
3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
|
|
AU2020278592B2
(en)
|
2019-05-17 |
2024-10-10 |
Nurix Therapeutics, Inc. |
Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
|
|
MX2021015675A
(es)
|
2019-06-26 |
2022-02-03 |
Nurix Therapeutics Inc |
Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
|
|
AU2020320195A1
(en)
|
2019-07-30 |
2022-03-10 |
Nurix Therapeutics, Inc. |
Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition
|
|
EP4034140A1
(en)
|
2019-09-24 |
2022-08-03 |
Nurix Therapeutics, Inc. |
Cbl inhibitors and compositions for use in adoptive cell therapy
|
|
US20230024442A1
(en)
|
2019-11-08 |
2023-01-26 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for grading btk via ubiquitin proteosome pathway
|
|
WO2021113557A1
(en)
*
|
2019-12-04 |
2021-06-10 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
|
|
AU2022310182A1
(en)
|
2021-07-14 |
2024-02-01 |
Nurix Therapeutics, Inc. |
Bifunctional compounds for degrading btk with diminished imid activity
|
|
CN118019539A
(zh)
|
2021-07-23 |
2024-05-10 |
纽力克斯治疗公司 |
用于降解BTK并具有增强的IMiD活性的双官能化合物
|
|
CA3236073A1
(en)
|
2021-10-26 |
2023-05-04 |
Robert J. Brown |
Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
|